Skip to content

Mucin Concentration in Sputum From COPD Patients During a Pulmonary Exacerbation

Molekularbiologische Eigenschaften Des Sputums während Einer Pulmonalen COPD Exacerbation

Status
Withdrawn
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01848093
Acronym
mucinCOPDex
Enrollment
0
Registered
2013-05-07
Start date
2008-12-31
Completion date
2013-07-31
Last updated
2016-11-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD

Keywords

lung, airway, pulmonary exacerbation, mucus

Brief summary

chronic obstructive pulmonary disease (COPD) is typically associated with mucus hypersecretion in the airways. In health, mucin is the major macromolecular component and is responsible for the protective and clearance properties of the mucus gel. In a recent study the investigators found that mucins are decreased and unstable in the sputum of adult cystic fibrosis (CF) patients. In this study the investigators want to investigate the differences on the mucin quantity and quality of airway secretions during pulmonary exacerbation of patients with COPD.

Detailed description

We hypothesize that during an exacerbation the mucin amount is increasing. The aim of this study is to evaluate the molecular (mucins) and structure properties (mucin-stability) of the airway secretions in COPD related to the severity of the disease. We characterize sputum composition of patients with pulmonary exacerbations. Using gel electrophoresis, with specific antibodies we will analyze MUC5AC and MUC5B mucins. The significance of these studies is that they will give us novel information about the pathogenesis of chronic inflammatory airway diseases, provide tools for assessing the progression of lung disease, and most critically, will identify novel opportunities and targets for therapeutic intervention.

Interventions

collecting of spontaneous sputum from the patient

Sponsors

Philipps University Marburg
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* forced expiratory volume at one second (FEV1) \< 80% * sputum production * clinical likely hood of exacerbation

Exclusion criteria

* FEV1 \> 80% or \< 30% * increased systemic inflammation * susceptibility of pneumonia * need for antibiotic treatment

Design outcomes

Primary

MeasureTime frameDescription
mucin concentration2 monthanalyzing mucin concentration by western

Secondary

MeasureTime frameDescription
mucin stability2 monthanalyzing mucin stability at 37C over 24 hours

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026